{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:53:08Z","timestamp":1791910388878,"version":"4.3.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204686"],"award-info":[{"award-number":["82204686"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Obesity has been historically associated with nonalcoholic fatty liver disease (NAFLD), but it can also occur in lean individuals. However, limited data is available on this special group. To investigate the clinical and proteomic characteristics of lean subjects with NAFLD, and to identify potential clinical variables and plasma proteins for diagnosing NAFLD in lean individuals, we collected clinical data from a large cohort of 2,236 subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Diagnosis of NAFLD relied on detecting pronounced hepatic steatosis through abdominal ultrasonography. Participants were categorized into four groups based on body mass index: overweight NAFLD, overweight control, lean NAFLD, and lean control. Plasma proteomic profiling was performed on samples from 20 subjects in each group. The lean NAFLD group was compared to both lean healthy and obese NAFLD groups across all data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and discussion<\/jats:title><jats:p>The results indicated that the lean NAFLD group exhibited intermediate metabolic profiles, falling between those of the lean healthy and overweight NAFLD groups. Proteomic profiling of plasma in lean subjects with or without NAFLD revealed 45 statistically significant changes in proteins, of which 37 showed high diagnostic value (AUC &amp;gt; 0.7) for lean NAFLD. These potential biomarkers primarily involved lipid metabolism, the immune and complement systems, and platelet degranulation. Furthermore, AFM, GSN, CFH, HGFAC, MMP2, and MMP9 have been previously associated with NAFLD or NAFLD-related factors such as liver damage, insulin resistance, metabolic syndromes, and extracellular homeostasis. Overall, lean individuals with NAFLD exhibit distinct clinical profiles compared to overweight individuals with NAFLD. Despite having worse metabolic profiles than their healthy counterparts, lean NAFLD patients generally experience milder systemic metabolic disturbances compared to obese NAFLD patients. Additionally, the plasma proteomic profile is significantly altered in lean NAFLD, highlighting the potential of differentially expressed proteins as valuable biomarkers or therapeutic targets for diagnosing and treating NAFLD in this population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1171397","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T18:02:48Z","timestamp":1700157768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuanye","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i36.6571","article-title":"Nonalcoholic fatty liver disease: Evolving paradigms","volume":"23","author":"Lonardo","year":"2017","journal-title":"World J Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.08.028","article-title":"Nonobese fatty liver disease","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in lean individuals","volume":"39","author":"Younes","year":"2019","journal-title":"Semin Liver Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608537103","article-title":"Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men","volume":"103","author":"Petersen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2016.00068","article-title":"Non-alcoholic fatty liver disease in lean subjects: Characteristics and implications","volume":"5","author":"Kumar","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15353","article-title":"A review of non-alcoholic fatty liver disease in non-obese and lean individuals","volume":"36","author":"Ahadi","year":"2021","journal-title":"J Gastroenterol Hepatol (Australia)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.28697","article-title":"Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients","volume":"65","author":"Leung","year":"2017","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.19.2169","article-title":"Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults","volume":"164","author":"Hae","year":"2004","journal-title":"Arch Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study","volume":"2","author":"Hagstr\u00f6m","year":"2018","journal-title":"Hepatol Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA - J Am Med Assoc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"942","DOI":"10.15252\/msb.20156297","article-title":"Revisiting biomarker discovery by plasma proteomics","volume":"13","author":"Geyer","year":"2017","journal-title":"Mol Syst Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2017.054","article-title":"Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry","volume":"12","author":"Keshishian","year":"2017","journal-title":"Nat Protoc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/msb.20188793","article-title":"Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease","volume":"15","author":"Niu","year":"2019","journal-title":"Mol Syst Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12685","article-title":"Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)","volume":"20","author":"Fan","year":"2019","journal-title":"J Dig Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12876-022-02290-1","article-title":"Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups","volume":"22","author":"Sugiyama","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01796-x","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020","volume":"56","author":"Tokushige","year":"2021","journal-title":"J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1322","article-title":"Universal sample preparation method for proteome analysis","volume":"6","author":"Wi\u015bniewski","year":"2009","journal-title":"Nat Methods"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28526","article-title":"Platelets: No longer bystanders in liver disease","volume":"64","author":"Chauhan","year":"2016","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1300","article-title":"Thyroid function and the risk of nonalcoholic fatty liver disease: The Rotterdam study","volume":"101","author":"Bano","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12216","article-title":"A cross-sectional study of the association between circulating TSH level and lipid profile in a large Spanish population","volume":"79","author":"Santos-Palacios","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040562","article-title":"NAFLD and chronic kidney disease","volume":"17","author":"Marcuccilli","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.05.019","article-title":"CKD and nonalcoholic fatty liver disease","volume":"64","author":"Targher","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088569","article-title":"Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease","volume":"9","author":"Sesti","year":"2014","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.12.9872","article-title":"Renal function status","volume":"200","author":"Becker","year":"2013","journal-title":"Am J Roentgenol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e7103","DOI":"10.5812\/hepatmon.7103","article-title":"Association of plasma retinol binding protein-4 (RBP4) and sonographic grading of fatty liver in obese Iranian children","volume":"12","author":"Saki","year":"2012","journal-title":"Hepat Mon"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature03711","article-title":"Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes","volume":"436","author":"Yang","year":"2005","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/14789450.2020.1810020","article-title":"Serum proteome assessment in nonalcoholic fatty liver disease in children: a preliminary study","volume":"17","author":"Ma\u0142ecki","year":"2020","journal-title":"Expert Rev Proteomics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/17460441.2018.1410135","article-title":"Non-alcoholic fatty liver disease (NAFLD) models in drug discovery","volume":"13","author":"Cole","year":"2018","journal-title":"Expert Opin Drug Discovery"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i26.8325","article-title":"Proteomic and genomic studies of non-alcoholic fatty liver disease - Clues in the pathogenesis","volume":"20","author":"Lim","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000688","article-title":"Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism","volume":"31","author":"Liu","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.09.072","article-title":"APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome","volume":"209","author":"Castro","year":"2010","journal-title":"Atherosclerosis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Sumida","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e02033","article-title":"Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia","volume":"5","author":"Boiko","year":"2019","journal-title":"Heliyon"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.4187","article-title":"A. Inter-\u03b1-trypsin inhibitor attenuates complement activation and complement-induced lung injury","volume":"179","author":"Garantziotis","year":"2007","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12614","article-title":"The serum proteome of nonalcoholic fatty liver disease: A multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis","volume":"29","author":"Miller","year":"2014","journal-title":"J Gastroenterol Hepatol (Australia)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.670425","article-title":"Serum afamin a novel marker of increased hepatic lipid content","volume":"12","author":"Kurdiova","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-07-0625","article-title":"Coagulation factor XIII: A multifunctional transglutaminase with clinical potential in a range of conditions","volume":"113","author":"Dickneite","year":"2015","journal-title":"Thromb Haemost"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqac059","article-title":"Sex-related association of nonalcoholic fatty liver disease and liver fibrosis with body fat distribution in the general US population","volume":"115","author":"Ciardullo","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-018-3212-1","article-title":"Laboratory parameters in lean NAFLD: Comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis","volume":"11","author":"Bernhardt","year":"2018","journal-title":"BMC Res Notes"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12580","article-title":"Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver","volume":"29","author":"Jiang","year":"2014","journal-title":"J Gastroenterol Hepatol (Australia)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.08.012","article-title":"Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis","volume":"50","author":"Guo","year":"2018","journal-title":"Dig Liver Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-017-0531-5","article-title":"Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults","volume":"16","author":"Zheng","year":"2017","journal-title":"Lipids Health Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/09537100903391023","article-title":"Mean platelet volume in patients with non-alcoholic fatty liver disease","volume":"21","author":"Ozhan","year":"2010","journal-title":"Platelets"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.842636","article-title":"Platelets in non-alcoholic fatty liver disease","volume":"13","author":"Dalbeni","year":"2022","journal-title":"Front Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI135105","article-title":"Complement factor H\u2013deficient mice develop spontaneous hepatic tumors","volume":"140","author":"Laskowski","year":"2020","journal-title":"J Clin Invest"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0700","article-title":"Complement factor H is expressed in adipose tissue in association with insulin resistance","volume":"59","author":"Moreno-Navarrete","year":"2010","journal-title":"Diabetes"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2015.04.010","article-title":"Afamin\u2013A pleiotropic glycoprotein involved in various disease states","volume":"446","author":"Dieplinger","year":"2015","journal-title":"Clin Chim Acta"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.670425","article-title":"Serum afamin a novel marker of increased hepatic lipid content","volume":"12","author":"Kurdiova","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23271","article-title":"Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease","volume":"51","author":"Bell","year":"2010","journal-title":"Hepatology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2174\/138920308786733912","article-title":"Plasma gelsolin: function, prognostic value, and potential therapeutic use","volume":"9","author":"Bucki","year":"2008","journal-title":"Curr Protein Pept Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2450\/2010.017S","article-title":"Plasma gelsolin protein: A candidate biomarker for hepatitis B-associated liver cirrhosis identified by proteomic approach","volume":"8","author":"Marrocco","year":"2010","journal-title":"Blood Transfusion"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3390\/ijms19092516","article-title":"Plasma gelsolin: Indicator of inflammation and its potential as a diagnostic tool and therapeutic target","volume":"19","author":"Piktel","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-27265-9","article-title":"Serum proteomic profiling to identify biomarkers of premature carotid atherosclerosis","volume":"8","author":"Bhosale","year":"2018","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19113435","article-title":"Hepatocyte growth factor activator: A proteinase linking tissue injury with repair","volume":"19","author":"Fukushima","year":"2018","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1171397\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T18:03:00Z","timestamp":1700157780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1171397\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":58,"alternative-id":["10.3389\/fendo.2023.1171397"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1171397","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"article-number":"1171397"}}